Popular:
Teva Pharmaceutical Industries Limited (TEVA)
Intrinsic Value (DCF)
Current$32.35
→
Intrinsic$50.98
+58%
$30.54$50.98$89.76
Market implies 16% growth for 5 years
DCF analysis suggests TEVA could have 58% upside at 25% growth — verify assumptions match your view.
At $32, the market prices in continued high-teens cash flow growth (16%) — likely reflecting buybacks, margin stability, and ecosystem strength.
Range: Bear $31 → Bull $90. Current price implies expectations below the base case, but well above the bear case.
| Discount ↓Growth → | 21% | 23% | 25% | 27% |
|---|---|---|---|---|
| 8% | $66 | $72 | $79 | $86 |
| 10% | $42 | $46 | $51 | $56 |
| 12% | $29 | $32 | $36 | $39 |
| 14% | $21 | $23 | $26 | $29 |
Bull Case
- Bull case ($90) offers 177% upside at 30% growth, 9% discount
- 37% margin of safety vs. base case estimate
- Market-implied growth (16%) ≤ historical CAGR (25%)
Bear Case
- Bear case ($31) implies 6% downside at 20% growth, 12% discount
- Using 25% growth — aggressive, watch for mean reversion
Loading charts...
5-Year Free Cash Flow Projection
Year 1$2.56B
Year 2$3.20B
Year 3$4.00B
Year 4$5.00B
Year 5$6.26B
Terminal$92.04B
📐 Model Inputs
Growth Rate25.0%5Y CAGR (cascade: 5Y→3Y→TTM)
Discount Rate10.0%WACC estimate
Terminal Growth3.0%Perpetuity rate
Base Free Cash Flow$2.05BTTM actual
Bear g×0.8, r+2%
Base Historical CAGR
Bull g×1.2, r−1.5%
DCF estimates based on historical growth rates extrapolated forward. See FAQ below for full methodology.